In preclinical murine xenograft models of HR(+) breast cancer, anti-endoglin monoclonal antibodies selectively inhibited tumor angiogenesis and delayed the growth of established tumors, while sparing normal vasculature [24]. Here, ENG is linked to breast cancer.